Search
Bismuth subgallate
go.drugbank.com/drugs/DB13909ApprovedBismuth subgallate is a yellow colored substance that presents as an odorless powder that undergoes discoloration when exposed to sunlight. … Possessing protective effects on the gastric mucosa, strong astringent effects, and not as yet elucidated antimicrobial and hemostatic actions, bismuth subgallate is most commonly available as an over-the-counter
Tenapanor
go.drugbank.com/drugs/DB11761ApprovedInvestigational[A185492] As an inhibitor of the sodium/hydrogen exchanger isoform 3 (NHE3) transporter, it is the first and currently only medication within its class[A185489,A185492,A185495] and therefore exists as … a novel alternative in the treatment of IBS-C.
Bamlanivimab
go.drugbank.com/drugs/DB15718ApprovedInvestigationalBamlanivimab (LY-CoV555, also known as LY3819253), is a synthetic monoclonal antibody (mAb) derived from one of the first blood samples in the United States from a patient who recovered from COVID-19. … for progressing to severe COVID-19:[L40179] this EUA later expanded in December 2021 to include all younger children at high risk, including newborns.
Custirsen
go.drugbank.com/drugs/DB05487InvestigationalCustirsen acts as a selective estrogen receptor modulator (SERM), inhibiting the proliferation of estrogen-sensitive breast cancer cells. … This agent also inhibits growth and induces apoptosis of glioblastoma cells via a mechanism independent of estrogen receptor-related mechanisms.
Flavoxate
go.drugbank.com/drugs/DB01148ApprovedIt may have local anesthetic activity and direct relaxing effects on smooth muscle as well as some activity as a muscarinic antagonist. [PubChem] … A drug that has been used in various urinary syndromes and as an antispasmodic. Its therapeutic usefulness and its mechanism of action are not clear.
Products: U-SPATopotecan
go.drugbank.com/drugs/DB01030ApprovedInvestigationalAn antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.
Categories: MATE 1 Substrates with a Narrow Therapeutic Index, MATE 2 Substrates with a Narrow Therapeutic IndexLumateperone
go.drugbank.com/drugs/DB06077ApprovedInvestigational[A189093] It has a unique receptor binding profile and differs from other antipsychotics in that it modulates glutamate, serotonin and dopamine, which are all neurotransmitters that contribute to the pathophysiology … Schizophrenia is a complex mental illness and impacts approximately 1% of the population.
Categories: Dopamine D2 Receptor Agonists, Serotonin Receptor AntagonistsHexylcaine
go.drugbank.com/drugs/DB00473ApprovedWithdrawnHexylcaine hydrochloride is also known as cyclaine and osmocaine. It is a short acting local anesthetic that acts through inhibition of sodium channels. … Patients experience an overdose may present with headache, tinnitus, numbness and tingling around the mouth and tongue, convulsions, inability to breathe, and decreased heart function.
Upadacitinib
go.drugbank.com/drugs/DB15091ApprovedInvestigational[A189171] The etiology of the disease is mostly unknown; however, the role of JAK as a driver of immune-mediated conditions was discovered, leading to the use of JAK as therapeutic targets for rheumatoid … Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression.
Cabotegravir
go.drugbank.com/drugs/DB11751ApprovedInvestigationalCabotegravir, or GSK1265744, is an HIV-1 integrase inhibitor that is prescribed with the non-nucleoside reverse transcriptase inhibitor, [rilpivirine]. … [L31198] While previously administered once monthly only, this combination product was granted FDA approval for dosing every two months on February 01, 2022 [L40084] and without the need for an oral lead-in